{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:59:23Z","timestamp":1790758763708,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,31]],"date-time":"2020-05-31T00:00:00Z","timestamp":1590883200000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.msard.2019.04.004","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T11:30:15Z","timestamp":1554895815000},"page":"173-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society"],"prefix":"10.1016","volume":"31","author":[{"given":"Christine","family":"Lebrun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vukusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2019.04.004_bib0032","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-0404.2008.01131.x","article-title":"Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations","volume":"119","author":"Ahlgren","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2019.04.004_bib0026","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/pds.3554","article-title":"Pooled analysis of large and long-term safety data from the human papillomavirus-16\/18-AS04-adjuvanted vaccine clinical trial program","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.msard.2019.04.004_bib0014","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM200102013440502","article-title":"Hepatitis B vaccination and the risk of multiple sclerosis","volume":"344","author":"Ascherio","year":"2001","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.msard.2019.04.004_bib0003","unstructured":"Audition publique \u2018Vaccination contre le virus de l'h\u00e9patite B et scl\u00e9rose en plaques: \u00e9tat des lieux\u2019. Rapport d'orientation de la commission d'audition du 24 novembre 2004). https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/VHB_audition%20publique.PDF, (accessed 28.12.2018)."},{"key":"10.1016\/j.msard.2019.04.004_bib0029","doi-asserted-by":"crossref","first-page":"d5956","DOI":"10.1136\/bmj.d5956","article-title":"Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden","volume":"343","author":"Bardage","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2019.04.004_bib0030","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1600-0404.1997.tb00075.x","article-title":"Multiple sclerosis in India: a case-control study of environmental exposures","volume":"95","author":"Bansil","year":"1997","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2019.04.004_bib0046","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1212\/WNL.0b013e31829e6fbf","article-title":"Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis","volume":"81","author":"Bar-Or","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.04.004_bib0051","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/NXI.0000000000000070","article-title":"Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens","volume":"2","author":"Bar-Or","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"issue":"Suppl 1","key":"10.1016\/j.msard.2019.04.004_bib0042","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0264-410X(02)00815-0","article-title":"A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis","volume":"21","author":"Baumhackl","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2019.04.004_bib0004","unstructured":"Bilan de pharmacovigilance et profil de s\u00e9curit\u00e9 d'emploi des vaccins contre l'h\u00e9patite B. February 2012. http:\/\/ansm.sante.fr\/content\/download\/38801\/509771\/version\/1\/file\/Bilan-VHB.pdf, (accessed 28.12.2018)."},{"key":"10.1016\/j.msard.2019.04.004_bib0056","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1177\/0091270011427908","article-title":"Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study","volume":"52","author":"Boulton","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2019.04.004_bib0063","unstructured":"Calendrier des vaccinations et recommandations vaccinales 2018. Minist\u00e8re de la Sant\u00e9 http:\/\/solidarites-sante.gouv.fr\/IMG\/pdf\/calendrier_vaccinations_2018.pdf."},{"key":"10.1016\/j.msard.2019.04.004_bib0021","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2796.2011.02467.x","article-title":"Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine","volume":"271","author":"Chao","year":"2012","journal-title":"J. Intern. Med."},{"issue":"46","key":"10.1016\/j.msard.2019.04.004_bib0059","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1016\/j.vaccine.2013.09.001","article-title":"Immunologic consequences of chemotherapy for ovarian cancer: impaired responses to the influenza vaccine","volume":"31","author":"Chu","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2019.04.004_bib0061","unstructured":"Club Rhumatismes et inflammations (CRI). Fiches pratiques et recommandations: www.cri-net.com\/."},{"key":"10.1016\/j.msard.2019.04.004_bib0034","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200102013440501","article-title":"Vaccines in Multiple Sclerosis Study Group. Vaccinations and the risk of relapse in multiple sclerosis","volume":"344","author":"Confavreux","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2019.04.004_bib0001","unstructured":"Conf\u00e9rence de consensus 2001 sur la scl\u00e9rose en plaques. https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/sclerose3.pdf, (accessed 28.12.2018)."},{"key":"10.1016\/j.msard.2019.04.004_bib0002","unstructured":"Conf\u00e9rence de consensus 2003 sur la vaccination contre l'h\u00e9patite B. https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/VHB_recos.pdf, (accessed 28.12.2018)."},{"key":"10.1016\/j.msard.2019.04.004_bib0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archneur.60.4.504","article-title":"Vaccinations and risk of central nervous system demyelinating diseases in adults","volume":"60","author":"DeStefano","year":"2003","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.msard.2019.04.004_bib0006","unstructured":"Development of Good Practice Guidelines. \u201cFormal consensus\u201d Method. December 2010, updated March 2015. https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2018-03\/good_practice_guidelines_fc_method.pdf. (accessed 28.12.2018)."},{"key":"10.1016\/j.msard.2019.04.004_bib0018","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3233\/HAB-150281","article-title":"Multiple sclerosis and immunological-related risk factors: results from a case-control study","volume":"23","author":"Eftekharian","year":"2014","journal-title":"Hum. Antibodies"},{"key":"10.1016\/j.msard.2019.04.004_bib0040","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archneurol.2011.131","article-title":"Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis","volume":"68","author":"Farez","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2019.04.004_bib0024","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12155","article-title":"Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects","volume":"275","author":"Grimaldi-Bensouda","year":"2014","journal-title":"J. Intern. Med"},{"key":"10.1016\/j.msard.2019.04.004_bib0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2017.01.005","article-title":"PGRx-AD Study Group. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J. Autoimmun"},{"key":"10.1016\/j.msard.2019.04.004_bib0019","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1212\/01.WNL.0000138433.61870.82","article-title":"Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study","volume":"63","author":"Hern\u00e1n","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.04.004_bib0054","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0000000000001302","article-title":"Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.04.004_bib0053","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2014.03.035","article-title":"Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis","volume":"341","author":"Kaufman","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2019.04.004_bib0009","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","article-title":"Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases","volume":"71","author":"Langer-Gould","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2019.04.004_bib0028","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amepre.2011.04.004","article-title":"H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project","volume":"41","author":"Lee","year":"2011","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.msard.2019.04.004_bib0060","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrneurol.2012.8","article-title":"Vaccination against infection in patients with multiple sclerosis","volume":"8","author":"Loebermann","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2019.04.004_bib0022","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system","volume":"313","author":"Madrid-Scheller","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2019.04.004_bib0057","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0b013e3182a35215","article-title":"Immune competence after alemtuzumab treatment of multiple sclerosis","volume":"81","author":"Mc Carthy","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.04.004_bib0037","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00415-011-5944-x","article-title":"Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination","volume":"258","author":"McNicholas","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2019.04.004_bib0048","doi-asserted-by":"crossref","first-page":"e78532","DOI":"10.1371\/journal.pone.0078532","article-title":"Preserved antigen specific immune response in patients with multiple sclerosis responding to IFNbeta-therapy","volume":"8","author":"Mehling","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2019.04.004_bib0055","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.22352","article-title":"Antigen-specific adaptative immune responses in fingolimod-treated multiple sclerosis patients","volume":"69","author":"Mehling","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2019.04.004_bib0011","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/brain\/awl368","article-title":"KIDSEP study group of the French Neuropaediatric Society. Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination","volume":"130","author":"Mikaeloff","year":"2007","journal-title":"Brain."},{"key":"10.1016\/j.msard.2019.04.004_bib0012","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1212\/01.wnl.0000335762.42177.07","article-title":"Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood","volume":"72","author":"Mikaeloff","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.04.004_bib0035","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1212\/WNL.48.2.312","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis","volume":"48","author":"Miller","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.04.004_bib0036","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/135245859700300405","article-title":"Influenza virus vaccination of patients with multiple sclerosis","volume":"3","author":"Mokhtarian","year":"1997","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.04.004_bib0062","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbspin.2015.08.008","article-title":"Vaccinations in adults with chronic inflammatory joint disease: immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs","volume":"83","author":"Morel","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.msard.2019.04.004_bib0043","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1212\/WNL.56.7.938","article-title":"Influenza vaccination in MS: absence of T-cell response against white matter proteins","volume":"56","author":"Moriabadi","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.04.004_bib0020","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.vaccine.2018.02.036","article-title":"Hepatitis B vaccination and the putative risk of central demyelinating diseases \u2013 A systematic review and meta-analysis","volume":"36","author":"Mouchet","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2019.04.004_bib0044","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1352458513513970","article-title":"Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study","volume":"20","author":"Olberg","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.04.004_bib0045","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2019.04.004_bib0050","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology.","volume":"130","author":"Orange","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.msard.2019.04.004_bib0031","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000080094","article-title":"Childhood infections as risk factors for multiple sclerosis: Belgrade case-control study","volume":"23","author":"Pekmezovic","year":"2004","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.msard.2019.04.004_bib0017","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000201564","article-title":"Canadian Collaborative Study Group. Association of infectious mononucleosis with multiple sclerosis. A population-based study","volume":"32","author":"Ramagopalan","year":"2009","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.msard.2019.04.004_bib0007","series-title":"The RAND\/UCLA Appropriateness Method User's Manual","year":"2001"},{"key":"10.1016\/j.msard.2019.04.004_bib0038","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1212\/WNL.53.7.1588","article-title":"Use of Bacille Calmette-Gu\u00e8rin (BCG) in multiple sclerosis","volume":"53","author":"Ristori","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.04.004_bib0039","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1212\/01.wnl.0000438216.93319.ab","article-title":"Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS","volume":"82","author":"Ristori","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.04.004_bib0041","first-page":"303","article-title":"Antibody response in seropositive multiple sclerosis patients vaccinated with attenuated live varicella zoster virus","volume":"7","author":"Ross","year":"1996","journal-title":"Can. J. Infect. Dis."},{"key":"10.1016\/j.msard.2019.04.004_bib0065","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/WNL.59.12.1837","article-title":"Immunization panel of the multiple sclerosis council for clinical practice guidelines. Immunization and MS: a summary of published evidence and recommendations","volume":"59","author":"Rutschmann","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.04.004_bib0016","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(99)02991-8","article-title":"School-based hepatitis B vaccination programme and adolescent multiple sclerosis","volume":"355","author":"Sadovnick","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2019.04.004_bib0047","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1212\/01.wnl.0000188901.12700.e0","article-title":"Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1-a","volume":"65","author":"Schwid","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.04.004_bib0058","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis","author":"Stokmaier","year":"2018","journal-title":"Am. Acad. Neurol."},{"key":"10.1016\/j.msard.2019.04.004_bib0010","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000059520","article-title":"Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study","volume":"21","author":"Touz\u00e9","year":"2002","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.msard.2019.04.004_bib0008","first-page":"242","article-title":"The first episode of central nervous system demyelinization and hepatitis B virus vaccination","volume":"156","author":"Touz\u00e9","year":"2000","journal-title":"Rev. Neurol"},{"key":"10.1016\/j.msard.2019.04.004_bib0052","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1179\/1743132812Y.0000000059","article-title":"Humoral immune response to influenza vaccine in natalizumab treated MS patients","volume":"34","author":"Vagberg","year":"2012","journal-title":"Neurol. Res."},{"key":"10.1016\/j.msard.2019.04.004_bib0066","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.3399\/bjgp09X472629","article-title":"Identification of new risk factors for pneumonia: population-based case-control study","volume":"59","author":"Vinogradova","year":"2009","journal-title":"Br. J. Gen. Pract."},{"key":"10.1016\/j.msard.2019.04.004_bib0049","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1212\/NXI.0000000000000409","article-title":"Immune response to vaccines is maintained in patients treated with dimethylfumarate","volume":"5","author":"Von Hehn","year":"2017","journal-title":"Neurol Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2019.04.004_bib0005","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.msard.2018.10.017","article-title":"Vaccines and disease-modifying treatments","volume":"26","author":"Waubant","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2019.04.004_bib0023","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1080\/21645515.2016.1199308","article-title":"Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16\/18 AS04-adjuvanted vaccine in the United Kingdom","volume":"12","author":"Willame","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.msard.2019.04.004_bib0033","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1600-0404.1996.tb00051.x","article-title":"Risk factors for multiple sclerosis: a case-control study in Israel","volume":"94","author":"Zilber","year":"1996","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2019.04.004_bib0013","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/12376","article-title":"No increase in demyelinating diseases after hepatitis B vaccination","volume":"5","author":"Zipp","year":"1999","journal-title":"Nat. Med"},{"key":"10.1016\/j.msard.2019.04.004_bib0027","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s10072-003-0147-6","article-title":"Risk factors of multiple sclerosis: a case-control study","volume":"24","author":"Zorzon","year":"2003","journal-title":"Neurol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819301646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819301646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:44:49Z","timestamp":1761900289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819301646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":65,"alternative-id":["S2211034819301646"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.04.004","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}